+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Pharmacogenomics Market Research Report by Technology (DNA Sequencing, Electrophoresis, and Mass Spectrometry), Application, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 247 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5716074
UP TO OFF until Mar 31st 2023
The Global Pharmacogenomics Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the Global Pharmacogenomics Market.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Pharmacogenomics Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Pharmacogenomics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Pharmacogenomics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Pharmacogenomics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Pharmacogenomics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Technology, the market is studied across DNA Sequencing, Electrophoresis, Mass Spectrometry, Microarray, and Polymerase Chain Reaction.
  • Based on Application, the market is studied across Drug Discovery, Neurology, Oncology, and Pain Management.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Pharmacogenomics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Pharmacogenomics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Pharmacogenomics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Pharmacogenomics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pharmacogenomics Market, including Admera Health, Agena Biosciences Inc., BiogeniQ Inc., CENTOGENE N.V., Coriell Life Sciences, Dynamic DNA Laboratorie, Empire Genomics, Illunima Inc., Myriad Genetics Inc., OneOme LLC, Personalis Inc., Phamatech Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., and ViennaLab Diagnostics GmbH.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Pharmacogenomics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmacogenomics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pharmacogenomics Market?
4. What is the competitive strategic window for opportunities in the Global Pharmacogenomics Market?
5. What are the technology trends and regulatory frameworks in the Global Pharmacogenomics Market?
6. What is the market share of the leading vendors in the Global Pharmacogenomics Market?
7. What modes and strategic moves are considered suitable for entering the Global Pharmacogenomics Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of chronic diseases and demand for precision medicine
5.1.1.2. Increasing investments for healthcare infrastructures
5.1.1.3. Technological advancements associated with molecular diagnostics procedure
5.1.2. Restraints
5.1.2.1. High costs associated with research and development proficiencies
5.1.3. Opportunities
5.1.3.1. Emerging trend of personalized medicines
5.1.3.2. Rising R&D activities to improve pharmacogenomics
5.1.4. Challenges
5.1.4.1. Dearth of awareness and required infrastructural facilities
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Pharmacogenomics Market, by Technology
6.1. Introduction
6.2. DNA Sequencing
6.3. Electrophoresis
6.4. Mass Spectrometry
6.5. Microarray
6.6. Polymerase Chain Reaction

7. Pharmacogenomics Market, by Application
7.1. Introduction
7.2. Drug Discovery
7.3. Neurology
7.4. Oncology
7.5. Pain Management

8. Americas Pharmacogenomics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Pharmacogenomics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Pharmacogenomics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Product Portfolio Analysis, By Key Player
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Admera Health
12.2. Agena Biosciences Inc.
12.3. BiogeniQ Inc.
12.4. CENTOGENE N.V.
12.5. Coriell Life Sciences
12.6. Dynamic DNA Laboratorie
12.7. Empire Genomics
12.8. Illunima Inc.
12.9. Myriad Genetics Inc.
12.10. OneOme LLC
12.11. Personalis Inc.
12.12. Phamatech Inc.
12.13. Quest Diagnostics
12.14. Thermo Fisher Scientific Inc.
12.15. ViennaLab Diagnostics GmbH

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL PHARMACOGENOMICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOGENOMICS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACOGENOMICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL PHARMACOGENOMICS MARKET DYNAMICS
FIGURE 11. GLOBAL PHARMACOGENOMICS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL PHARMACOGENOMICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TECHNOLOGY, 2030
FIGURE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
FIGURE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
FIGURE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 22. GLOBAL PHARMACOGENOMICS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2030
FIGURE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
FIGURE 25. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
FIGURE 26. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
FIGURE 27. AMERICAS PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 28. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 29. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 30. AMERICAS PHARMACOGENOMICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 31. ARGENTINA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 32. BRAZIL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 33. CANADA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 34. MEXICO PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 35. UNITED STATES PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 37. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 38. UNITED STATES PHARMACOGENOMICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 39. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 41. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 42. ASIA-PACIFIC PHARMACOGENOMICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 43. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. CHINA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. INDIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 46. INDONESIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. JAPAN PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. MALAYSIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. SINGAPORE PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. TAIWAN PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. THAILAND PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. VIETNAM PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 57. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 58. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 59. DENMARK PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. EGYPT PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. FINLAND PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. FRANCE PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. GERMANY PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. ISRAEL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. ITALY PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. NIGERIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. NORWAY PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. POLAND PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. QATAR PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. RUSSIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. SPAIN PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. SWEDEN PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. TURKEY PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. GLOBAL PHARMACOGENOMICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 81. GLOBAL PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 82. GLOBAL PHARMACOGENOMICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL PHARMACOGENOMICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 46. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 47. CANADA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. MEXICO PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. MEXICO PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. CHINA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 63. CHINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. CHINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. INDIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. INDIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 67. INDIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. JAPAN PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 72. JAPAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. JAPAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. TAIWAN PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. THAILAND PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 90. THAILAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 91. THAILAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. VIETNAM PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 93. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. DENMARK PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 100. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. DENMARK PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. EGYPT PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 103. EGYPT PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. EGYPT PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. FINLAND PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 106. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. FINLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. FRANCE PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 109. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. FRANCE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. GERMANY PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 112. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. GERMANY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. ISRAEL PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 115. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. ITALY PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. ITALY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. ITALY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 121. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. NIGERIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. NORWAY PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 127. NORWAY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. NORWAY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. POLAND PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 130. POLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. POLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. QATAR PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. QATAR PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. QATAR PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. SPAIN PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 145. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. SPAIN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. SWEDEN PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 151. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. TURKEY PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 154. TURKEY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. TURKEY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. GLOBAL PHARMACOGENOMICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 163. GLOBAL PHARMACOGENOMICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 164. GLOBAL PHARMACOGENOMICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 165. GLOBAL PHARMACOGENOMICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 166. GLOBAL PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 167. GLOBAL PHARMACOGENOMICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 168. GLOBAL PHARMACOGENOMICS MARKET MERGER & ACQUISITION
TABLE 169. GLOBAL PHARMACOGENOMICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 170. GLOBAL PHARMACOGENOMICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 171. GLOBAL PHARMACOGENOMICS MARKET INVESTMENT & FUNDING
TABLE 172. GLOBAL PHARMACOGENOMICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 173. GLOBAL PHARMACOGENOMICS MARKET: LICENSE & PRICING

Companies Mentioned

  • Admera Health
  • Agena Biosciences Inc.
  • BiogeniQ Inc.
  • CENTOGENE N.V.
  • Coriell Life Sciences
  • Dynamic DNA Laboratorie
  • Empire Genomics
  • Illunima Inc.
  • Myriad Genetics Inc.
  • OneOme LLC
  • Personalis Inc.
  • Phamatech Inc.
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
  • ViennaLab Diagnostics GmbH

Methodology

Loading
LOADING...